The article discusses the use of Tecovirimat, an antiviral drug, for the treatment of monkeypox infection. Monkeypox is a zoonotic orthopoxvirus that has caused a recent global outbreak with over 50,000 cases reported. Tecovirimat inhibits p37, a protein involved in the release of the virus, and has shown activity against both smallpox and monkeypox. The study assessed adverse events and clinical resolution of symptoms and lesions in patients with monkeypox who were treated with tecovirimat on a compassionate use basis.